Middle East Alzheimer’s Disease Drugs Market Report 2022 to 2030

Middle East Alzheimer’s Disease Drugs Market Analysis

$ 3999

Middle East Alzheimer’s Disease Drugs market was valued at $617 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.42% from 2022 to 2030 and will reach $1267 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies and government initiatives. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Johnson and Johnson, Lupin Limited, Biogen Inc, Pfizer Inc, F. Hoffmann-La Roche AG, Novartis AG, Allergan Plc (acquired by Abbvie), Amarantus Bioscience Holdings Inc, and GE Healthcare.

ID: IN10MEPH006 CATEGORY: Pharmaceuticals GEOGRAPHY: Middle East AUTHOR: Nandini Shah

Buy Now

Middle East Alzheimer’s Disease Drugs Market Executive Summary

Middle East Alzheimer’s Disease Drugs market was valued at $617 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.42% from 2022 to 2030 and will reach $1267 Mn in 2030. Alzheimer's disease is characterized by nerve cell degeneration throughout the brain. It impairs cognitive functions such as memory, language, thinking, and behavior. Sadness, memory loss, loss of inhibitions, and problems with thinking and reasoning are all prevalent Alzheimer's Disease symptoms. Medical examinations, blood tests, brain imaging, and mental status and neuropsychological testing are commonly used to make the diagnosis. Based on the findings, doctors prescribe various medications to alleviate symptoms. Medication for Alzheimer's disease affects the activity of neurotransmitters, which are chemicals that convey impulses between nerve cells in the brain.

The increasing prevalence of Alzheimer's disease in the Middle East region, along with the growing aging population, is driving the demand for Alzheimer's drugs in the region. In addition, the increasing awareness and early diagnosis of Alzheimer's disease are also contributing to market growth.

middle east alzheimers disease drugs market analysis

Market Dynamics

Market Growth Drivers

The Middle East region has witnessed a significant increase in the prevalence of Alzheimer's disease over the years, mainly due to the growing aging population. As per the estimates of the World Health Organization (WHO), the number of people with dementia in the Middle East region is expected to increase from 4.7 Mn in 2020 to 9.7 Mn by 2050. This increasing prevalence of Alzheimer's disease is one of the major growth drivers of the market. The awareness of Alzheimer's disease and the importance of early diagnosis have been increasing in the Middle East region. This is mainly due to the efforts of healthcare organizations, governments, and NGOs to spread awareness about the disease and the benefits of early diagnosis. The increasing awareness has led to more people seeking medical attention at an early stage, which, in turn, is driving the demand for Alzheimer's drugs. The healthcare industry in the Middle East is witnessing significant technological advancements in the field of Alzheimer's disease. The development of new drugs, along with advanced diagnostic techniques, is driving the growth of the market. For instance, in 2018, the United Arab Emirates (UAE) became the first country in the world to launch a dementia-friendly initiative, which aims to improve the quality of life of people with dementia and their families through the use of technology. Governments in the Middle East are taking several initiatives to improve the healthcare infrastructure and services in the region. For instance, the Saudi Arabian government has launched a national dementia plan to improve the care and treatment of people with dementia. Such government initiatives are driving the growth of the Alzheimer's drugs market in the Middle East.

Market Restraints

Access to quality healthcare is still limited in some parts of the Middle East, particularly in rural areas. This can make it difficult for people with Alzheimer's disease to access the care and treatment they need. The cost of Alzheimer's drugs is often high, and this can be a significant barrier to treatment for many people in the Middle East, particularly those who do not have health insurance or whose insurance does not cover the cost of the drugs. The regulatory environment for pharmaceuticals in the Middle East can be complex and challenging. Companies often need to navigate a range of regulations and requirements before they can bring their drugs to market. Generic drugs are increasingly available in the Middle East, and they often offer a cheaper alternative to branded drugs. This can make it difficult for companies to maintain market share and profitability.

Competitive Landscape

Key Players

Abbvie
AstraZeneca
Amarantus Bioscience Holdings Inc
GE Healthcare.
Biogen
Eisai Co.
Eli Lilly and Company
H. Lundbeck A/S
Johnson and Johnson
F. Hoffmann-La Roche AG
Novartis AG
Pfizer

Healthcare Policies and Regulatory Landscape

The Middle East Association for Age and Ageing and Alzheimer's (MEAAA) is an organization that focuses on promoting healthy aging and providing care for older adults in the Middle East. The organization also focuses on raising awareness about Alzheimer's disease and other dementias and promoting research into the causes and treatment of these conditions. MEAAA was established in 2002 and has since been involved in various initiatives and programs aimed at improving the quality of life for older adults in the Middle East. The organization has partnerships with various national and international organizations, including the World Health Organization (WHO).

According to a report published by the MEAAA in 2017, the prevalence of dementia in the Middle East is expected to increase significantly in the coming years due to an aging population. The report estimates that by 2050, there will be approximately 14 Mn people living with dementia in the region. The report also highlights the need for increased awareness, education, and resources to address this growing issue.

Reimbursement Scenario

The reimbursement scenario for Alzheimer's drugs in the Middle East can vary depending on the country and healthcare system. Generally, healthcare systems in the Middle East are still developing, and reimbursement policies for pharmaceuticals can be complex and vary between countries.

In some countries, such as the United Arab Emirates, the government provides free or subsidized healthcare services to citizens and residents, including prescription drugs. In these cases, Alzheimer's drugs may be covered by the government-funded healthcare system, but coverage may be limited to certain drugs and may be subject to approval criteria.

In other countries, such as Saudi Arabia, healthcare services are primarily provided by the private sector, and patients may be required to pay out-of-pocket for their medications. In these cases, reimbursement for Alzheimer's drugs may depend on the patient's insurance coverage or ability to pay.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Alzheimer's Disease Drugs Market Segmentation

By Drug Class (Revenue, USD Billion)

Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (Memantine)
Combination Drugs
Others (Lecanemab, Aducanumab)

Drug segmentation is the process of dividing a set of drugs into different categories or classes based on their pharmacological properties, therapeutic uses, and other characteristics. Here, Alzheimer’s Disease Drugs Market is segmented into Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Combination Drugs, and others like (Lecanemab, Aducanumab)

By Distribution Channel (Revenue, USD Billion)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Route of Administration

Oral
Transdermal
Intravenous

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.